2024
A novel microporous biomaterial vaccine platform for long-lasting antibody mediated immunity against viral infection
Mayer D, Nelson M, Andriyanova D, Filler R, Ökten A, Antao O, Chen J, Scumpia P, Weaver W, Wilen C, Deshayes S, Weinstein J. A novel microporous biomaterial vaccine platform for long-lasting antibody mediated immunity against viral infection. Journal Of Controlled Release 2024, 370: 570-582. PMID: 38734312, PMCID: PMC11665867, DOI: 10.1016/j.jconrel.2024.05.008.Peer-Reviewed Original ResearchAntigen delivery platformGerminal centersCD4<sup>+</sup> T follicular helper (Tfh) cellsT follicular helper (Tfh) cellsAdaptive immune cell responsesOptimal adaptive immune responsesAnti-receptor binding domain antibodiesInfluenza virus challengeRobust neutralizing antibodiesImmune cell responsesEnhanced neutralizing antibodiesAdaptive immune responsesDelivery platformAntibody mediated immunityLymph nodesVaccine platformNeutralizing antibodiesHumoral immunitySARS-CoV-2 spike proteinSustained release profileTarget antigenImmune responseVirus challengeViral infectionCell responses
2017
Consecutive inoculations of influenza virus vaccine and poly(I:C) protects mice against homologous and heterologous virus challenge
Moriyama M, Chino S, Ichinohe T. Consecutive inoculations of influenza virus vaccine and poly(I:C) protects mice against homologous and heterologous virus challenge. Vaccine 2017, 35: 1001-1007. PMID: 28111142, DOI: 10.1016/j.vaccine.2017.01.025.Peer-Reviewed Original ResearchMeSH KeywordsAdjuvants, ImmunologicAdministration, IntranasalAnimalsAntibodies, ViralCross ProtectionFemaleFormaldehydeImmunity, MucosalImmunization ScheduleImmunoglobulin AImmunoglobulin GInfluenza A Virus, H1N1 SubtypeInfluenza A Virus, H3N2 SubtypeInfluenza VaccinesMiceMice, Inbred BALB COrthomyxoviridae InfectionsPoly I-CSurvival AnalysisVaccines, InactivatedConceptsInfluenza virus vaccinePrimary immune responseVirus vaccineIntranasal vaccinationVirus challengeImmune responseInactivated influenza virus vaccineInfluenza virusHeterologous influenza virus challengeVirus-specific IgAInfluenza virus challengeHeterologous virus challengeNatural infectionSerum IgG responsesConsecutive inoculationsSingle intranasal vaccinationCross-protective activityNasal IgANasal washesIgG responsesMucosal immunitySystemic immunityVaccinationNaïve animalsVaccine
1999
Attenuated Vesicular Stomatitis Viruses as Vaccine Vectors
Roberts A, Buonocore L, Price R, Forman J, Rose J. Attenuated Vesicular Stomatitis Viruses as Vaccine Vectors. Journal Of Virology 1999, 73: 3723-3732. PMID: 10196265, PMCID: PMC104148, DOI: 10.1128/jvi.73.5.3723-3732.1999.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCattleCell LineCricetinaeFemaleGene ExpressionGenetic VectorsHemagglutinin Glycoproteins, Influenza VirusInfluenza VaccinesMembrane GlycoproteinsMiceMice, Inbred BALB COrthomyxoviridae InfectionsRecombination, GeneticTime FactorsVaccines, AttenuatedVaccines, SyntheticVesicular stomatitis Indiana virusViral Envelope ProteinsVirionConceptsVesicular stomatitis virusLethal influenza virus challengeComplete protectionInfluenza virus challengeRecombinant vesicular stomatitis virusSingle intranasal vaccinationInfluenza virus HAStomatitis virusIntranasal vaccinationLethal challengeIntranasal administrationVirus challengeMouse modelVaccine vectorVSV vectorsVirus HAInfluenza virusHemagglutinin proteinInfluenza virus hemagglutinin (HA) proteinG proteinsPathogenesisVirus hemagglutinin proteinVirusPresent studyVaccination
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply